Mitoxantrone-Associated Acute Myelogenous Leukemia in a Patient with High-Risk Adenocarcinoma of the Prostate: A Case Report and Brief Review

REFERENCES

• Topcu Z. DNA topoisomerases as targets for anticancer drugs. J. Clin. Pharm. Ther. 2001; 26: 405–416, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996; 14: 1756–1764, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kantoff P. W., Halabi S., Conaway M., Picus J., Kirshner J., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999; 17: 2506–2513, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Petrylak D. P., Tangen C. M., Hussain M. H., Lara P. N., Jones J. A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 35: 1513–1520, [CSA], [CROSSREF]
   Google Scholar
• Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–1512, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Specht L., Larsen S. O., Ersboll J., Struck J., et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; 2: 83–88, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Rowley J. D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–2786, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Felix C. A. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 2001; 36: 525–535, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Pui C. H., Relling M. V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br. J. Haematol. 2000; 109: 13–23, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Andersen M. K., Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J. Clin. Oncol. 1998; 16: 1897–1998, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rowley J. D., Vignon C., Gollin S. M., Rosenberg C. L., Wyandt H. E., Milunsky A. Chromosomal translocations in secondary acute myeloid leukemia. N. Engl. J. Med. 1996; 334: 601–603, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang Y., Strissel P., Strick R., Chen J., Nucifora G., et al. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I. hypersensitive sites in t(8;21) leukemia. Proc. Natl. Acad. Sci. USA 2002; 99: 3070–3075, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beaumont M., Sanz M., Carli P. M., Maloisel F., Thomas X., et al. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 2003; 21: 2123–2137, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mistry A. R., Felix C. A., Whitmarsh R. J., Mason A., et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 2005; 352: 1529–1538, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Roulston D., Anastasi J., Rudinsky R., Nucifora G., Zeleznik-Le N., et al. Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases. Blood 1995; 86: 3613–3614, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Takeda K., Shinohara K., Kameda N., Ariyoshi K. A case of therapy-related acute myeloblastic leukemia with t(16;21) (q24;q22) after chemotherapy with DNA-topoisomerase II. inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. Int. J. Hematol. 1998; 67: 179–186, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Voltz R., Starck M., Zingler V., Strupp M., Kolb H. J. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult. Scler. 2004; 10: 472–474, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Novoselac A. V., Reddy S., Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004; 18: 1561–1562, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hessen C., Bruegmann M., Gbdamosi J., Koch E., Monch A., Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult. Scler. 2003; 9: 213–214, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Andersson M., Philip P., Pedersen-Bjergaard J. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 1990; 65: 2460–2464, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Linassier C., Barin C., Calais G., Letortorec S., Bremond J. L., et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann. Oncol. 2000; 11: 1289–1294, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cremin P., Flattery M., McCann S. R., Daly P. A. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann. Oncol. 1996; 7: 745–746, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Saso R., Kulkarni S., Mitchell P., Treleaven J., Swansbury G. J., et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br. J. Cancer 2000; 83: 91–94, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chaplain G., Milan C., Sgro C., Carli P. M., Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J. Clin. Oncol. 2000; 18: 2836–2842, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kroger N., Damon L., Zander A. R., Wandt H., Derigs G., et al. Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transpl. 2003; 32: 1153–1157, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Katato K., Flaherty L., Varterasian M. Secondary acute myelogenous leukemia following treatment with oral etoposide. Am. J. Hematology 1996; 53: 54–55, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kossman S. E., Weiss M. A. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer 2000; 88: 620–624, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Matsuura H, Sakurai M, Arima K. Two cases of prostate cancer associated with acute myeloid leukemia presenting as thrombocytopenia during endocrine therapy. Acta Urologica Japonica 2003; 49: 87–90, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Andersen M. K., Larson R. A., Mauritzson N., Schnittger S., Jhanwar S. C., Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 395–400, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bloomfield C. D., Lawrence D., Byrd J. C., Carroll A., Pettenati M. J., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemias varies by cytogenetic subtype. Cancer Res. 1998; 58: 4173–9, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dissing M., Le Beau M. M., Pedersen-Bjergaard J. J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?. J. Clin. Oncol. 1998; 16: 1890–1896, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar